Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development
Brisbin, Abra G
Asmann, Yan W
Aakre, Jeremiah A
Jenkins, Robert B
Conti, David V
Duggan, David J
Sellers, Thomas A
Fridley, Brooke L
MetadataShow full item record
Brisbin, A. G., Asmann, Y. W., Song, H., Tsai, Y., Aakre, J. A., Yang, P., Jenkins, R. B., et al. (2011). Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development.
Abstract Background Human chromosomal region 8q24 contains several genes which could be functionally related to cancer, including the proto-oncogene c-MYC. However, the abundance of associations around 128 Mb on chromosome 8 could mask the appearance of a weaker, but important, association elsewhere on 8q24. Methods In this study, we completed a meta-analysis of results from nine genome-wide association studies for seven types of solid-tumor cancers (breast, prostate, pancreatic, lung, ovarian, colon, and glioma) to identify additional associations that were not apparent in any individual study. Results Fifteen SNPs in the 8q24 region had meta-analysis p-values < 1E-04. In particular, the region consisting of 120,576,000-120,627,000 bp contained 7 SNPs with p-values < 1.0E-4, including rs6993464 (p = 1.25E-07). This association lies in the region between two genes, NOV and ENPP2, which have been shown to play a role in tumor development and motility. An additional region consisting of 5 markers from 128,478,000 bp - 128,524,000 (around gene POU5F1B) had p-values < 1E-04, including rs6983267, which had the smallest p-value (p = 6.34E-08). This result replicates previous reports of association between rs6983267 and prostate and colon cancer. Conclusions Further research in this area is warranted as these results demonstrate that the chromosomal region 8q24 may contain a locus that influences general cancer susceptibility between 120,576 and 120,630 kb.
This record's URL: http://www.dspace.cam.ac.uk/handle/1810/241603
Rights Holder: Brisbin et al.; licensee BioMed Central Ltd.